Vipdomet

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
PSUSA/10061 /202304	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	30/11/2023	n/a		PRAC Recommendation - maintenance
II/0044	Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vitamin B12 decrease or deficiency and to update the list of adverse drug reactions (ADRs) in accordance with the recent update of the PI for Glucophage, which is the reference label for the compound metformin, and	26/10/2023		SmPC and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	following the request by MHRA on 20 June 2022 for all products containing metformin. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IB/0043	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	24/05/2023	n/a		
WS/2397/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	26/01/2023	n/a		

IG/1566	A.7 - Administrative change - Deletion of manufacturing sites	10/10/2022	n/a		
WS/2327	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier	15/09/2022	n/a		
N/0040	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/09/2022		PL	
WS/2191	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of a consolidated RMP version 11.1 for Vipidia, Vipdomet and Incresync in order to: - Update the RMPs for Alogliptin, Alogliptin/Pioglitazone fixed dose combination (FDC) and Alogliptin/Metformin fixed dose combination (FDC) to consolidate within a single RMP as committed within the PSUR procedure (PSUSA/00010061/202104). - Following review of cumulative safety data, removal of a number of safety concerns is done	10/06/2022	n/a		n/a

	based on GVP Module V, Risk Management Systems (revision 2) guidelines. - Remove the target follow up Questionnaires of Severe Hypersensitivity and skin reactions, Pancreatitis, Hepatic events and follow up gastrointestinal events and infections from Alogliptin and Alo/Met RMPs. - Reflect the removal of the inverted black triangle as agreed as part of the alogliptin renewal procedure (EMEA/H/C/002178/R/0023) for Alogliptin and the FDC Alogliptin/Metformin. The black triangle was already removed from the FDC Alogliptin/Pioglitazone RMP as part of the Type II variation (EMEA/H/C/002178/II/0029). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IG/1486/G	This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or	13/04/2022	n/a		

	manufacturer of a novel excipient				
IB/0037/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.z - Quality change - Finished product - Other variation	11/03/2022	n/a		
N/0035	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/11/2021	04/04/2022	PL	
PSUSA/10061 /202104	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	28/10/2021	n/a		PRAC Recommendation - maintenance
IB/0034/G	This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	17/08/2021	n/a		
WS/1967/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No	18/03/2021	04/04/2022	SmPC, Annex II, Labelling and PL	

	1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.1 - Administrative change - Change in the name and/or address of the MAH				
WS/1966	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test	14/01/2021	n/a		
PSUSA/10061 /202004	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	12/11/2020	07/01/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10061/202004.
IAIN/0031	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)	21/12/2020	n/a		
PSUSA/10061 /201904	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	31/10/2019	n/a		PRAC Recommendation - maintenance
IG/1071/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a	28/03/2019	n/a		

	starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold				
PSUSA/10061 /201804	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	31/10/2018	n/a		PRAC Recommendation - maintenance
R/0024	Renewal of the marketing authorisation.	22/03/2018	24/05/2018	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vipidia in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
PSUSA/10061 /201704	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	26/10/2017	n/a		PRAC Recommendation - maintenance
IB/0023	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/10/2017	24/05/2018	SmPC	
WS/1235/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No	14/09/2017	n/a		

	1234/2008. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
IA/0020/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	11/05/2017	n/a		
IB/0019	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	28/03/2017	n/a		
A31/0015	Pursuant to Article 31 of Regulation (EC) No 726/2004, the European Commission requested on 25 January 2016 the opinion of the European	13/10/2016	12/12/2016	SmPC and PL	Please refer to the assessment report: Metformin containing medicinal products - EMEA/H/A-31/1432

	Medicines Agency on the adequacy of the current recommendations for metformin containing products with respect to the use in patients with moderate renal failure, taking into account the available information on the risk of lactic acidosis. The CHMP was requested to assess the impact thereof on the benefit-risk balance of metformin containing products and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. The notification for the procedure is appended to this opinion.				
PSUSA/10061 /201604	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	27/10/2016	n/a		PRAC Recommendation - maintenance
IG/0734/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	13/10/2016	n/a		

	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size				
WS/0940	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	28/04/2016	n/a		
IG/0652	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	22/01/2016	n/a		
PSUSA/10061 /201504	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	06/11/2015	n/a		PRAC Recommendation - maintenance
IB/0012/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary	14/08/2015	n/a		

	packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place				
PSUSA/10061 /201410	Periodic Safety Update EU Single assessment - alogliptin, alogliptin / metformin, alogliptin / pioglitazone	10/04/2015	n/a		PRAC Recommendation - maintenance
PSUV/0008	Periodic Safety Update	20/11/2014	15/01/2015	SmPC and PL	Please refer to Vipdomet PSUV/08 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
IAIN/0010	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	21/11/2014	15/01/2015	SmPC, Labelling and PL	
IAIN/0009/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	21/11/2014	15/01/2015	SmPC, Labelling and PL	
WS/0519	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	24/07/2014	15/01/2015	SmPC	Results from study 402, a phase 3b, randomised, double-blind, placebo-controlled, event-driven study, which was designed to demonstrate that no excess risk of a major adverse cardiovascular event (MACE) exists following

	The WSA proposed the update of sections 4.4, 4.8, and 5.1 of the SmPC and in order to reflect the results of study 402, a phase 3b, randomised, double-blind, placebo-controlled, event-driven study, designed to demonstrate that no excess risk of a major adverse cardiovascular event (MACE) exists following treatment with alogliptin compared with placebo when added to standard of care in adults with type II diabetes mellitus (T2DM) and acute coronary syndrome (ACS). The MAH took this opportunity to propose amendments to the RMP in order to reflect results from study 402 and to update its structure according to the new European Union (EU) template for RMPs. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				treatment with alogliptin compared with placebo when added to standard of care in adults with type II diabetes mellitus (T2DM) and acute coronary syndrome (ACS), are included in the SmPC. The primary endpoint of the study was achieved, demonstrating non-inferiority of alogliptin compared with placebo for the primary MACE composite. Therefore, in general, alogliptin was not associated with an increased risk of cardiovascular disease.
WS/0520	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	24/07/2014	15/01/2015	SmPC	
PSUV/0005	Periodic Safety Update	12/06/2014	n/a		PRAC Recommendation - maintenance
IB/0007	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	05/05/2014	n/a		

II/0006	Update of section 4.4 of the SmPC in order to update the safety information on acute pancreatitis. The Package Leaflet is updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	25/04/2014	15/01/2015	SmPC and PL	The scope of this variation was to update section 4.4 of the SmPC to update the safety information on acute pancreatitis following recommendations of an Art 5(3) procedure on GLP-1-based therapies and pancreatic safety. The Package Leaflet is updated accordingly. The benefit/risk balance of Vipdomet remains unchanged.
IG/0401	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	11/02/2014	n/a		